GlassScriptPhysician profile
Neysan Bayat
NPI 1962509901
$5,002.60
in general payments reported to CMS, 2019-2025
7 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $127 · 2021: $472 · 2022: $723 · 2023: $1,388 · 2024: $1,328 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $3,088.91 | 2019-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Surgiclose |
| Stryker Corporation | $803.50 | 2019-2025 | Variax, Conextions Tr Tendon Repair System-Implant Mechanism, Hoffmann |
| Kci USA, INC. | $324.55 | 2019-2023 | Activ.A.C. |
| Ethicon US, LLC | $313.52 | 2023 | Echelon; Endopath, Monocryl, Evarrest |
| Sanara Medtech INC. | $212.88 | 2024 | Celleraterx |
| Acera Surgical, INC. | $155.77 | 2019 | |
| Teleflex LLC | $103.47 | 2024 | Quikclot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neysan Bayat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.